Clinical Trial · NCT04481230

Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer

Overview

This study is a phase I clinical trial aimed to determine the recommended dose of 99mTc-NTP 15-5 to obtain the best tracer joints contrast on images without any toxicity.

Sponsor

Centre Jean Perrin

Phase

Early Phase 1

Contacts

Florent CACHIN, Pr (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04481230

Eligibility

Inclusion

Age \<60 yearsCommon inclusion criteria:
signed written informed consent.
Patient with at least 31 healthy joints (based on clinical assessment)
Patient with non-metastatic breast cancer, hormone receptor positive, HER2 negative, with indication for adjuvant therapy with aromatase inhibitor; treatment not yet started.
Inclusion criteria specific to group 1:\- Patient with painful unilateral osteoarthritis of the knee as femorotibial pattern defined by a radiographic score of 0/1 from Kellgren / Lawrence and an average WOMAC score\> or equal to 4 and by minor disorders at MRI (MOCART 2.0 score\> 70).Inclusion criteria specific to group 2:

Exclusion

BMI\> 30
* Patients \<18 years of age.
Pregnant or lactating patient.
Chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, etc.) diffuse arthritis (at least 3 joints affected), autoimmune connectivitis, fibromyalgia.
History of known allergy to excipients contained in the solution of 99mTc-NTP 15-5